Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.2 USD | +0.16% | -5.91% | +77.57% |
08/05 | Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
07/05 | Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.57% | 53Cr | |
+7.30% | 11TCr | |
+11.01% | 11TCr | |
+1.02% | 2.23TCr | |
-12.19% | 2.22TCr | |
-5.52% | 1.94TCr | |
-37.85% | 1.79TCr | |
-5.99% | 1.72TCr | |
+7.05% | 1.43TCr | |
+34.83% | 1.25TCr |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Wedbush Trims Y-mAbs Therapeutics' Price Target to $12 From $13, Keeps Outperform Rating